China Biologic Products (NASDAQ:CBPO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Monday.
According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Separately, BidaskClub raised shares of China Biologic Products from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 20th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. China Biologic Products has an average rating of “Hold” and a consensus target price of $137.50.
China Biologic Products (CBPO) traded down $1.72 during mid-day trading on Monday, hitting $78.70. 164,120 shares of the company were exchanged, compared to its average volume of 199,655. China Biologic Products has a 52-week low of $72.21 and a 52-week high of $120.46. The stock has a market cap of $2,660.00, a PE ratio of 20.49, a PEG ratio of 1.02 and a beta of 1.67.
A number of institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new stake in China Biologic Products in the 4th quarter valued at about $117,000. Wasatch Advisors Inc. boosted its position in China Biologic Products by 66.1% in the 4th quarter. Wasatch Advisors Inc. now owns 228,373 shares of the biopharmaceutical company’s stock valued at $17,989,000 after buying an additional 90,891 shares during the period. Vontobel Asset Management Inc. boosted its position in China Biologic Products by 54.3% in the 4th quarter. Vontobel Asset Management Inc. now owns 87,846 shares of the biopharmaceutical company’s stock valued at $6,920,000 after buying an additional 30,918 shares during the period. AXA boosted its position in China Biologic Products by 35.9% in the 3rd quarter. AXA now owns 128,220 shares of the biopharmaceutical company’s stock valued at $11,831,000 after buying an additional 33,886 shares during the period. Finally, California Public Employees Retirement System boosted its position in China Biologic Products by 51.7% in the 3rd quarter. California Public Employees Retirement System now owns 44,757 shares of the biopharmaceutical company’s stock valued at $4,130,000 after buying an additional 15,257 shares during the period. 52.34% of the stock is owned by institutional investors.
China Biologic Products Company Profile
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.